Chiesi Global Rare Diseases Expands Clinical Evidence for Fabry and Alpha-Mannosidosis Therapies — Chiesi Farmaceutici S.p.A. (Chiesi Global Rare Diseases)

Event summary

Chiesi Global Rare Diseases presented 13 scientific abstracts at the SSIEM 2026 Annual Symposium, including 6 Chiesi-led studies and 7 independently supported research projects.
Key presentations focused on long-term Phase 3 data from the F60/BRILLIANCE trial for Fabry disease and earlier diagnosis insights for alpha-mannosidosis.
Chiesi highlighted patient-reported outcomes and real-world clinical experiences in both Fabry disease and alpha-mannosidosis.
The company announced the second edition of its Find For Rare research grant initiative to advance knowledge in lysosomal storage disorders.

The big picture

Chiesi Global Rare Diseases is reinforcing its position in the lysosomal storage disorders space by expanding its clinical evidence base. The presentations at SSIEM 2026 underscore the company's focus on long-term data and patient-centric research, which are critical for differentiating its therapies in a competitive rare disease market. The strategic emphasis on early diagnosis and real-world outcomes aligns with broader industry trends toward personalized and precision medicine.

What we're watching

Clinical Validation: How the long-term Phase 3 data from the F60/BRILLIANCE trial will impact regulatory and commercial positioning of Elfabrio in Fabry disease treatment.
Diagnostic Advances: Whether the phenotypic similarity approach for alpha-mannosidosis detection can accelerate early diagnosis and treatment initiation.
Research Funding: The pace at which Chiesi's Find For Rare initiative will drive innovative research in lysosomal storage disorders.